

# Coronavirus Disease 2019 (COVID-19) Situation Report

Data as reported by national authorities by 23:00 local time 06<sup>th</sup> of January 2021

Situation Report No. 212 - State of Kuwait  
07<sup>th</sup> of January, 2021




	Global		Eastern Mediterranean Region	
	COVID-19 Cases	COVID-19 Deaths	COVID-19 Cases	COVID-19 Deaths
<b>Total</b>	85,091,012	1,861,005	5,044,647	123,329
<b>New</b>	585,557	11,632	23,805	433

## State of Kuwait

	Confirmed Cases	Recovered Cases	Deaths	Active Cases	Critical Cases	PCR Tests
<b>Total</b>	152,438	148,015	938	3,485	56	1,287,755
<b>New</b>	411	231	0	-	-	10,558


## HIGHLIGHTS

- Preparation are underway to launch mobile units next February to vaccinate people with disabilities and special needs which will coincide with the arrival of the first batch of Asrtazenecca Oxford vaccine.
- Coronavirus recovery rate reached 97.1%.
- WHO produces evidence to recommendations: Methods used for assessing health equity and human rights considerations in COVID-19 and aviation, see link.
- WHO publishes guidance on COVID-19 global risk communication and community engagement strategy, see link.
- WHO produces a prepared daft by the SAGE on COVID-19 vaccines.



## IMPORTANT LINKS

- MoH update of COVID-19: <https://corona.e.gov.kw/en/>
- WHO's COVID-19 weekly situation reports: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports>
- WHO's COVID-19 dashboard: <https://covid19.who.int/>
- WHO Recommendations on methods used for assessing health equity and human rights considerations in COVID-19 and aviation: <https://www.who.int/publications/i/item/evidence-to-recommendations-methods-used-for-assessing-health-equity-and-human-rights-considerations-in-covid-19-and-aviation>
- WHO guidance on COVID-19 Global Risk Communication and Community Engagement Strategy: <https://www.who.int/publications/i/item/covid-19-global-risk-communication-and-community-engagement-strategy>
- Draft on Immunization Working Group on COVID-19 vaccines: <https://www.who.int/publications/i/item/mrna-vaccines-against-covid-19-pfizer-biotech-covid-19-vaccinebnt162b2>




## IMPORTANT DEFINITIONS

### WHO issues its first emergency use validation for a COVID-19 vaccine

The World Health Organization listed the Comirnaty COVID-19 mRNA vaccine for emergency use, making the Pfizer/BioNTech vaccine the first to receive emergency validation from WHO. This opens the door for countries to expedite their own regulatory approval processes to import and administer the vaccine.

Regulatory experts convened by WHO from around the world and WHO's own teams reviewed the data on the vaccine's safety, efficacy and quality as part of a risk-versus-benefit analysis. Experts from individual national authorities are invited to participate in the review. The review found that the vaccine met the must-have criteria for safety and efficacy set out by WHO, and that the benefits of using the vaccine to address COVID-19 offset potential risks.

The vaccine is also under policy review to formulate vaccine specific policies and recommendations for this product's use in populations.



## IMPORTANT CONTACTS

- The National Focal Person is Dr Buthaina AIMudhaf, Assistant Undersecretary, Ministry of Health, email: AIMudhaf@gmail.com